CLEOs Test Advances Ovarian Cancer Detection

In Melbourne, Cleo Diagnostics Limited (ASX: COV) revealed their ovarian cancer triage test's latest peer-reviewed study in "Diagnostics" journal, showcasing superior accuracy over the CA125 marker. The test notably identifies most ovarian cancer cases overlooked by CA125, including early-stage cancers, significantly reducing false positives.

This advancement not only enhances patient triage for surgery but also positions CLEO's technology as pivotal for early cancer detection strategies. CEO Richard Allman emphasized the test's potential to transform clinical investigations, enabling precise patient management and supporting regulatory approvals. The study underscores CLEO's test's capacity to accurately distinguish between malignant and benign conditions, marking a substantial improvement in ovarian cancer diagnostics and patient care.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com